123794-13-8 Usage
Uses
Used in Pharmaceutical Industry:
MNIP is utilized as a pharmaceutical intermediate for the synthesis of a variety of drugs, leveraging its unique chemical structure to contribute to the development of novel therapeutic agents.
Used in Antimicrobial Applications:
MNIP is employed for its antimicrobial properties, serving as a potential component in the creation of new medications aimed at treating infectious diseases caused by bacteria and other microorganisms.
Used in Antifungal Applications:
The antifungal attributes of MNIP make it a valuable asset in the development of medications designed to combat fungal infections, offering an alternative or adjunct to existing antifungal treatments.
Used in Cancer Research and Therapy:
MNIP's potential to inhibit the growth of certain cancer cells positions it as a candidate for further research and development in oncology. It may contribute to cancer treatment strategies, particularly if its mechanism of action can be harnessed to target specific types of cancer cells effectively.
Further research is necessary to fully explore the range of applications for MNIP and to optimize its use in various therapeutic areas. As our understanding of (3Z)-1-methyl-3-[(1-methyl-4-nitro-1H-imidazol-2-yl)methylidene]pyrrolidin-2-one grows, so too may its potential impact on the fields of medicine and healthcare.
Check Digit Verification of cas no
The CAS Registry Mumber 123794-13-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,3,7,9 and 4 respectively; the second part has 2 digits, 1 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 123794-13:
(8*1)+(7*2)+(6*3)+(5*7)+(4*9)+(3*4)+(2*1)+(1*3)=128
128 % 10 = 8
So 123794-13-8 is a valid CAS Registry Number.
123794-13-8Relevant academic research and scientific papers
New 5-nitroimidazoles bearing lactame nucleus: Synthesis and antibacterial properties
Jentzer,Vanelle,Crozet,Maldonado,Barreau
, p. 687 - 697 (2007/10/02)
New 5-nitroimidazoles bearing a trisubstituted ethylenic double bond in position 2 were prepared by reacting various 1-alkyl-2-chloromethyl-5-nitroimidazole with 3-nitrolactam anions by S(RN)1 mechanism in phase-transfer catalysis conditions. These compounds showed in vitro and in vivo antianaerobic activity which was clearly greater than that of metronidazole. Structure-activity relationships have been discussed.
